Literature DB >> 18257128

BRCA1/2 associated hereditary breast cancer.

Li-song Teng1, Yi Zheng, Hao-hao Wang.   

Abstract

Breast cancer is one of the leading causes of death in women today. Some of the patients are hereditary, with a large proportion characterized by mutation in BRCA1 and/or BRCA2 genes. In this review, we provide an overview of these two genes, focusing on their relationship with hereditary breast cancers. BRCA1/2 associated hereditary breast cancers have unique features that differ from the general breast cancers, including alterations in cellular molecules, pathological bases, biological behavior, and a different prevention strategy. But the outcome of BRCA1/2 associated hereditary breast cancers still remains controversial; further studies are needed to elucidate the nature of BRCA1/2 associated hereditary breast cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18257128      PMCID: PMC2225488          DOI: 10.1631/jzus.B0710617

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  35 in total

1.  Quality of life after bilateral prophylactic mastectomy.

Authors:  Ann M Geiger; Larissa Nekhlyudov; Lisa J Herrinton; Sharon J Rolnick; Sarah M Greene; Carmen N West; Emily L Harris; Joann G Elmore; Andrea Altschuler; In-Liu A Liu; Suzanne W Fletcher; Karen M Emmons
Journal:  Ann Surg Oncol       Date:  2006-11-11       Impact factor: 5.344

2.  Survival and prognostic factors in BRCA1-associated breast cancer.

Authors:  C T M Brekelmans; C Seynaeve; M Menke-Pluymers; H T Brüggenwirth; M M A Tilanus-Linthorst; C C M Bartels; M Kriege; A N van Geel; C M G Crepin; J C Blom; H Meijers-Heijboer; J G M Klijn
Journal:  Ann Oncol       Date:  2005-12-01       Impact factor: 32.976

3.  A screening for BRCA1 mutations in breast and breast-ovarian cancer families from the Stockholm region.

Authors:  M Zelada-Hedman; B Wasteson Arver; A Claro; J Chen; B Werelius; H Kok; K Sandelin; S Håkansson; T I Andersen; A Borg; A L Børresen Dale; A Lindblom
Journal:  Cancer Res       Date:  1997-06-15       Impact factor: 12.701

4.  Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.

Authors: 
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

Review 5.  The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications.

Authors:  Emiliano Honrado; Javier Benítez; José Palacios
Journal:  Mod Pathol       Date:  2005-10       Impact factor: 7.842

6.  BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway.

Authors:  J J Chen; D Silver; S Cantor; D M Livingston; R Scully
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

7.  Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.

Authors:  D Cortez; Y Wang; J Qin; S J Elledge
Journal:  Science       Date:  1999-11-05       Impact factor: 47.728

8.  Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Authors:  Anne Uyei; Susan K Peterson; Julie Erlichman; Kristine Broglio; Sandra Yekell; Kathkeen Schmeler; Karen Lu; Funda Meric-Bernstam; Chris Amos; Louise Strong; Banu Arun
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

9.  Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status.

Authors:  Pal Moller; D Gareth Evans; Marta M Reis; Helen Gregory; Elaine Anderson; Lovise Maehle; Fiona Lalloo; Anthony Howell; Jaran Apold; Neal Clark; Anneke Lucassen; C Michael Steel
Journal:  Int J Cancer       Date:  2007-09-01       Impact factor: 7.396

10.  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.

Authors:  Gad Rennert; Shantih Bisland-Naggan; Ofra Barnett-Griness; Naomi Bar-Joseph; Shiyu Zhang; Hedy S Rennert; Steven A Narod
Journal:  N Engl J Med       Date:  2007-07-12       Impact factor: 91.245

View more
  8 in total

1.  BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients.

Authors:  Fatemeh Keshavarzi; Gholam Reza Javadi; Sirous Zeinali
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

2.  Cytogenetic and cDNA microarray expression analysis of MCF10 human breast cancer progression cell lines.

Authors:  Narasimharao V Marella; Kishore S Malyavantham; Jianmin Wang; Sei-ichi Matsui; Ping Liang; Ronald Berezney
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

3.  Breast and Ovarian Cancer Risk due to Prevalence of BRCA1 and BRCA2 Variants in Pakistani Population: A Pakistani Database Report.

Authors:  Ayesha Farooq; Abdul Khaliq Naveed; Zahid Azeem; Tausif Ahmad
Journal:  J Oncol       Date:  2011-03-24       Impact factor: 4.375

4.  Natural and glucosyl flavonoids inhibit poly(ADP-ribose) polymerase activity and induce synthetic lethality in BRCA mutant cells.

Authors:  Junko Maeda; Erica J Roybal; Colleen A Brents; Mitsuru Uesaka; Yasushi Aizawa; Takamitsu A Kato
Journal:  Oncol Rep       Date:  2013-12-05       Impact factor: 3.906

5.  Mutation Spectrum of Cancer-Associated Genes in Patients With Early Onset of Colorectal Cancer.

Authors:  Gulnur Zhunussova; Georgiy Afonin; Saltanat Abdikerim; Abai Jumanov; Anastassiya Perfilyeva; Dilyara Kaidarova; Leyla Djansugurova
Journal:  Front Oncol       Date:  2019-08-02       Impact factor: 6.244

6.  Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era.

Authors:  Gabriel S Macedo; Barbara Alemar; Patricia Ashton-Prolla
Journal:  Genet Mol Biol       Date:  2019-04-29       Impact factor: 1.771

7.  Detection of single amino acid mutation in human breast cancer by disordered plasmonic self-similar chain.

Authors:  Maria Laura Coluccio; Francesco Gentile; Gobind Das; Annalisa Nicastri; Angela Mena Perri; Patrizio Candeloro; Gerardo Perozziello; Remo Proietti Zaccaria; Juan Sebastian Totero Gongora; Salma Alrasheed; Andrea Fratalocchi; Tania Limongi; Giovanni Cuda; Enzo Di Fabrizio
Journal:  Sci Adv       Date:  2015-09-04       Impact factor: 14.136

8.  Brca2 deficiency drives gastrointestinal tumor formation and is selectively inhibited by mitomycin C.

Authors:  Xiaomin Chen; Fangfei Peng; Yan Ji; Honggang Xiang; Xiang Wang; Tingting Liu; Heng Wang; Yumin Han; Changxu Wang; Yongfeng Zhang; Xiangyin Kong; Jing-Yu Lang
Journal:  Cell Death Dis       Date:  2020-09-26       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.